SUNPHARMA's weekly performance was disappointing, with a return of -0.86% and a Sharpe Ratio of -1.30, indicating poor risk-adjusted returns. The stock's volatility was relatively low at 3.53%, but its Max Drawdown of -0.86% suggests some downside risk. Compared to its peers, SUNPHARMA outperformed DRREDDY and HINDUNILVR but underperformed DIVISLAB. Overall, the stock's risk profile was moderate this week.

[Volatility: 3.53%]